Elagox 150 mg (Tablet)

Indications

• Management of moderate to severe pain associated with endometriosis

Pharmacology

• GnRH receptor antagonist
• Inhibition of endogenous GnRH signaling
• Competitive binding to pituitary gland GnRH receptors
• Suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
• Decreased blood concentrations of estradiol and progesterone

Dosage & Administration

• Exclusion of pregnancy before treatment
• Initiation within 7 days from the onset of menses
• Initial treatment with Elagolix 150 mg
• Initial treatment with Elagolix 200 mg
• Consideration for hepatic impairment
• Use not established in children and adolescents

Interaction

• Potential impact on medicine metabolism
• Potential food interaction

Contraindications

• Pregnancy
• Known osteoporosis
• Severe hepatic impairment
• Concomitant use of OATP1B1 inhibitors

Side Effects

• Common side effects
• Rare side effects

Pregnancy & Lactation

• Limited human data
• Risk of early pregnancy loss
• Contraindicated in pregnant women
• Discontinuation if pregnancy occurs
• Unknown effects on breastfed child and milk production

Precautions & Warnings

• Bone loss
• Reduced ability to recognize pregnancy
• Suicidal ideation and mood disorders
• Hepatic transaminase elevations
• Potential for reduced efficacy with contraceptives

Use in Special Populations

• No dose adjustment in women with renal impairment
• No dosage adjustment in women with mild hepatic impairment
• Safety and effectiveness not established in patients less than 18 years of age

Overdose Effects

• Monitoring for signs or symptoms
• Symptomatic treatment

Therapeutic Class

• Gonadotropin-releasing hormone (GnRH) antagonist

Storage Conditions

• Cool and dry storage
• Protection from light and moisture
• Keep out of reach of children

Related Brands

• Egolix 200 mg (Tablet) - acme-laboratories-ltd